<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02408731</url>
  </required_header>
  <id_info>
    <org_study_id>CT-430-CENT-2012</org_study_id>
    <nct_id>NCT02408731</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Safety, Tolerability and Pharmacokinetics of PMZ-2010 (Centhaquin) in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase I Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of PMZ-2010 (Centhaquin) in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmazz, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmazz, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Shock is a condition of reduced tissue perfusion, resulting in the inadequate delivery of&#xD;
      oxygen and nutrients that are necessary for cellular function. The current resuscitative&#xD;
      agents can extend patient's life to a limited extent. Centhaquin (PMZ-2010) in very low doses&#xD;
      reduced blood lactate levels, improved blood pressure, cardiac output, survival and proved to&#xD;
      be a highly effective resuscitative agent. The investigators are conducting a phase I&#xD;
      clinical study in humans to evaluate the safety, tolerability, pharmacokinetics and&#xD;
      pharmacodynamics of centhaquin citrate in normal healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Shock is a condition of reduced tissue perfusion, resulting in the inadequate delivery of&#xD;
      oxygen and nutrients that are necessary for cellular function. Common causes of shock are&#xD;
      hypovolemia (excessive blood or fluid loss), sepsis, cardiac failure, dengue and&#xD;
      neuroendocrine dysfunction. The current resuscitative measures include administration of&#xD;
      crystalloid solutions (e.g., 0.9% saline, Ringer's lactate, or hypertonic saline) or colloid&#xD;
      solutions (e.g., hydroxyethyl starch, albumin, or dextrans). These agents can extend&#xD;
      patient's life to a limited extent. Centhaquin (PMZ-2010) in very low doses reduced blood&#xD;
      lactate levels, improved blood pressure, cardiac output, survival and proved to be a highly&#xD;
      effective resuscitative agent. The investigators are conducting a phase I clinical study in&#xD;
      humans to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of&#xD;
      centhaquin citrate in normal healthy volunteers. Successful completion of phase I studies&#xD;
      will lead to efficacy studies in patients with hypovolemic shock.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>7 days</time_frame>
    <description>Measure blood pressure, heart rate, body temperature, ECG, laboratory parameters and clinical assessment.after single and multiple ascending doses of PMZ-2010.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of pharmacokinetics of PMZ-2010 in plasma</measure>
    <time_frame>24 hours</time_frame>
    <description>Maximum concentration (Cmax), Time of maximum plasma concentration (Tmax), Area under the concentration-time curve (AUC) from time of dosing to the last quantifiable concentration (AUClast), Terminal elimination half-life (t½), Clearance (CL/F), Apparent volume of distribution during the terminal elimination phase (Vz/F) of PMZ-2010 in plasma after single ascending doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phamacodynamics profile of PMZ-2010</measure>
    <time_frame>7 days</time_frame>
    <description>Change in systolic and diastolic blood pressure, pulse rate, heart rate, QTcF after single ascending dose and multiple ascending doses</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single dose of 0.005 mg/kg of PMZ-2010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 0.005 mg/kg of PMZ-2010 (n=3) or placebo (n=1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of 0.01 mg/kg of PMZ-2010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 0.01 mg/kg of PMZ-2010 (n=3) or placebo (n=1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of 0.05 mg/kg of PMZ-2010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 0.05 mg/kg of PMZ-2010 (n=3) or placebo (n=1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of 0.10 mg/kg of PMZ-2010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 0.10 mg/kg of PMZ-2010 (n=3) or placebo (n=1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 doses equivalent to MTD of PMZ-2010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three equally divided doses (total dose/day equivalent to MTD) of PMZ-2010 (n=3) or placebo (n=1) for 2 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 doses equivalent to 2*MTD of PMZ-2010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three equally divided doses (total dose/day equivalent to 2*MTD) of PMZ-2010 (n=3) or placebo (n=1) for 2 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PMZ-2010 (Centhaquin)</intervention_name>
    <description>As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.</description>
    <arm_group_label>3 doses equivalent to 2*MTD of PMZ-2010</arm_group_label>
    <arm_group_label>3 doses equivalent to MTD of PMZ-2010</arm_group_label>
    <arm_group_label>Single dose of 0.005 mg/kg of PMZ-2010</arm_group_label>
    <arm_group_label>Single dose of 0.01 mg/kg of PMZ-2010</arm_group_label>
    <arm_group_label>Single dose of 0.05 mg/kg of PMZ-2010</arm_group_label>
    <arm_group_label>Single dose of 0.10 mg/kg of PMZ-2010</arm_group_label>
    <other_name>Placebo (normal saline)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Subjects to be enrolled in this trial must fulfill all of these&#xD;
        criteria:&#xD;
&#xD;
          -  Sex: male&#xD;
&#xD;
          -  Age: 18-60 yr old, both inclusive&#xD;
&#xD;
          -  Having a Body Mass Index (BMI) between 18.5-28 kg / m2 (both inclusive) and body&#xD;
             weight not less than 45 kg&#xD;
&#xD;
          -  Full comprehension: ability to comprehend the full nature and purpose of the study,&#xD;
             including possible risks and side effects; and to comply with the requirements of the&#xD;
             entire study&#xD;
&#xD;
          -  Voluntarily given written informed consent to participate in this study&#xD;
&#xD;
          -  Be of normal health as determined by the principal investigator from medical history,&#xD;
             physical examination and laboratory investigations, 12-lead ECG and X-ray chest of the&#xD;
             subjects performed within 10 days prior to the admission of the study&#xD;
&#xD;
          -  Ability and willingness to abstain from alcohol, methylxanthine-containing beverages&#xD;
             or food (coffee, tea, coke, chocolate, &quot;power drinks&quot;) and grapefruit (juice) from 48&#xD;
             h prior to each admission until study completion&#xD;
&#xD;
        Exclusion Criteria: Subjects meeting any of these criteria will not be enrolled in the&#xD;
        study:&#xD;
&#xD;
          -  Employees of JCDC or Pharmazz India Private Limited&#xD;
&#xD;
          -  Not willing to use contraceptives (preferably condoms) during sexual activity for the&#xD;
             period of 3 months from the date of check-in&#xD;
&#xD;
          -  History of hypersensitivity and / or intolerance to Centhaquin or any other related&#xD;
             compounds.&#xD;
&#xD;
          -  History of anaphylaxis to drugs or allergic reactions in general, which the&#xD;
             Investigator considers may affect the outcome of the study.&#xD;
&#xD;
          -  Clinically abnormal ECG and Chest X-ray.&#xD;
&#xD;
          -  Physical findings: clinically relevant abnormal physical findings (including body&#xD;
             temperature) suggesting underlying pathologies or those which could interfere with the&#xD;
             objectives of the study.&#xD;
&#xD;
          -  Subjects with impaired renal function as measured by glomerular filtration rate &lt;90&#xD;
             mL/min/1.73m2 estimated using the modification of diet in renal disease (MDRD) formula&#xD;
             [GFR for Male =186 × (Serum Creatinine)-1.154 × Age-0.203 ]12&#xD;
&#xD;
          -  Laboratory values that are significantly different than the normal reference range&#xD;
             and/or are deemed to be of clinical significance by the investigator&#xD;
&#xD;
          -  Presence of reactive disease markers of HIV 1 and II, HBsAg, HCV or VDRL.&#xD;
&#xD;
          -  Positive for alcohol breath test and/or urine drug screen (barbiturates,&#xD;
             benzodiazepines, amphetamine, cocaine, opiates, tetra-hydro cannabinol).&#xD;
&#xD;
          -  Any evidence of organ dysfunction or any clinically significant deviation from the&#xD;
             normal, in physical or clinical determinations.&#xD;
&#xD;
          -  Diseases: relevant history of renal, hepatic, cardiovascular, respiratory, skin,&#xD;
             haematological, endocrine, neurological or gastrointestinal diseases. History of&#xD;
             depression, psychosis, schizophrenia or any other severe psychiatric diseases, or&#xD;
             epilepsy, or any other illness that may interfere with the aim of the study. History&#xD;
             of any significant illness in the 4 weeks preceding the screening&#xD;
&#xD;
          -  Medications: history of intake of any medications including over the counter&#xD;
             medications (OTC) and any herbal agents at least 4 weeks period prior to study drug&#xD;
             administration.&#xD;
&#xD;
          -  Investigational drug trials: participation in the evaluation of any drug in the 3&#xD;
             months prior to the start of the study (dosing with IMP).&#xD;
&#xD;
          -  Blood donation: Subjects who, through completion of this study, would have donated&#xD;
             and/or lost more than 300 mL of blood in the past 12 weeks Note: In case the blood&#xD;
             loss is ≤ 200 mL; subject may be dosed 60 days after blood donation or last sample of&#xD;
             the previous study&#xD;
&#xD;
          -  Regular smokers who smoke more than 10 cigarettes daily or have difficulty abstaining&#xD;
             from smoking for the duration of each study period.&#xD;
&#xD;
          -  History of drug dependence or alcoholics&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashish O Goyal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jehangir Clinical Development Centre Pvt. Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jahangir Clinical Development Centre Pvt. Ltd.</name>
      <address>
        <city>Pune</city>
        <state>Maharastra</state>
        <zip>Pune 411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Gulati A, Zhang Z, Murphy A, Lavhale MS. Efficacy of centhaquin as a small volume resuscitative agent in severely hemorrhaged rats. Am J Emerg Med. 2013 Sep;31(9):1315-21. doi: 10.1016/j.ajem.2013.05.032. Epub 2013 Jul 19.</citation>
    <PMID>23871440</PMID>
  </reference>
  <reference>
    <citation>Lavhale MS, Havalad S, Gulati A. Resuscitative effect of centhaquin after hemorrhagic shock in rats. J Surg Res. 2013 Jan;179(1):115-24. doi: 10.1016/j.jss.2012.08.042. Epub 2012 Sep 2.</citation>
    <PMID>22964270</PMID>
  </reference>
  <reference>
    <citation>Gulati A, Lavhale MS, Garcia DJ, Havalad S. Centhaquin improves resuscitative effect of hypertonic saline in hemorrhaged rats. J Surg Res. 2012 Nov;178(1):415-23. doi: 10.1016/j.jss.2012.02.005. Epub 2012 Apr 2.</citation>
    <PMID>22487389</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>March 20, 2015</study_first_submitted>
  <study_first_submitted_qc>March 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2015</study_first_posted>
  <last_update_submitted>April 26, 2015</last_update_submitted>
  <last_update_submitted_qc>April 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <pending_results>
    <submitted>June 19, 2018</submitted>
    <returned>December 27, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

